Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | TEC | P42680 | 1/20 | 0.45 |
| ▸ | TXK | P42681 | 1/20 | 0.45 |
| ▸ | BLK | P51451 | 1/20 | 0.45 |
| ▸ | BMX | P51813 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31158074 | 0.90 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL14913070 | 0.90 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL14914054 | 0.90 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL29741838 | 0.90 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL29741839 | 0.90 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL14916195 | 0.90 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL14917004 | 0.87 | BTK (0.49) | BTK | |
| SCHEMBL14915716 | 0.87 | BTK (0.49) | BTK | |
| SCHEMBL14915717 | 0.87 | BTK (0.49) | BTK | |
| SCHEMBL26630688 | 0.85 | BTK (0.47) | BTKEGFRERBB2TECTXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606566-B2 | Substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazines as bruton's tyrosine kinase inhibitors | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| US-20230348471-A1 | BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606566-B2 | Substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazines as bruton's tyrosine kinase inhibitors | BTK, LYN, SYK | BTK 1/4885EGFR 998/4885ERBB2 80/4885 |
| US-20230348471-A1 | BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | BTK, SYK, LCK | BTK 1/4885EGFR 1361/4885ERBB2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.